Fronczyk A, Majkowska L. Białko C-reaktywne w cukrzycy. Diabetol Dośw Klin 2004; 4: 255–259.
K ing DE, Mainous AG III, Buchanan TA, et al. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 2003; 26: 1535–1539.
Chao C, Song Y, Cook N, et al. The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2010; 170: 1557–1565.
K olcowa O, Orłowska-Kunikowska E, Semetkowska-Jurkiewicz E, i wsp. Ocena wybranych markerów procesu zapalnego u chorych na cukrzycę typu 2. Diabetol Dośw Klin 2003; 3(1): 41–46.
K eavney B. More evidence against a causal association between C-reactive protein and diabetes. PLoS Med 2008;5(8): E174.
K ope-Szlęzak J. Cytokiny w procesach odpornościowych. Onkol Pol 2005; 8(4): 217–222.
Murphy CA, Langrish CL, Chen Y, et al. Pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.5(8): E174.JEM 2003; 198(12): 1951–1957.
Lankford CSR, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J Leukocyte Biology 2003; 73:49–56.
Y udkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscle Throm Vasc Biol 1999; 19: 972–978